Earnings Summary

Black Diamond Therapeutics’s net profit jumped 16.48% since last year same period to $-19.15Mn in the Q2 2023. On a quarterly growth basis, Black Diamond Therapeutics has generated 8.25% jump in its net profits since last 3-months.

Black Diamond Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.63 - a 1.56% jump from last quarter’s estimates.

Black Diamond Therapeutics’s earning per share (EPS) estimates for the current year stand at -0.63.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Black Diamond Therapeutics’s return on assets (ROA) stands at -0.34.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Black Diamond Therapeutics’s return on equity (ROE) stands at -0.71.